Literature DB >> 26732155

Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men.

Giovanni Corona1, Silvia Bianchini1, Alessandra Sforza1, Linda Vignozzi2, Mario Maggi2.   

Abstract

There is evidence demonstrating that sexual complaints represent the most specific symptoms associated with late onset hypogonadism, while central obesity is the most specific sign. In obese men, hypogonadism can further worsen the metabolic profile and increase abdominal fat. In addition, although hypogonadism can exacerbate obesity-associated erectile dysfunction (ED), recent data suggest that a direct contribution of fat-derived factors could be hypothesized. In particular, an animal model recently documented that fat accumulation induces several hepatic pro-inflammatory genes closely linked to corpora cavernosa endothelial dysfunction. Lifestyle modifications and weight loss are the first steps in the treatment of ED patients with obesity or metabolic diseases. In symptomatic hypogonadal men with metabolic impairment and obesity, combining the effect of testosterone substitution with lifestyle modifications could result in better outcomes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26732155     DOI: 10.14310/horm.2002.1635

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  18 in total

1.  Downregulation of miR-200a Protects Mouse Leydig Cells Against Triptolide by Triggering Autophagy.

Authors:  Hui Miao; Congxiu Miao; Jing Han; Na Li
Journal:  Drug Des Devel Ther       Date:  2020-11-10       Impact factor: 4.162

2.  Can the positive association of osteocalcin with testosterone be unmasked when the preeminent hypothalamic-pituitary regulation of testosterone production is impaired? The model of spinal cord injury.

Authors:  A Barbonetti; S D'Andrea; J Samavat; A Martorella; G Felzani; S Francavilla; M Luconi; F Francavilla
Journal:  J Endocrinol Invest       Date:  2018-05-04       Impact factor: 4.256

Review 3.  Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs.

Authors:  Giovanni Corona; Andrea M Isidori; Antonio Aversa; Marco Bonomi; Alberto Ferlin; Carlo Foresta; Sandro La Vignera; Mario Maggi; Rosario Pivonello; Linda Vignozzi; Francesco Lombardo
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

Review 4.  Testosterone Replacement Therapy: Long-Term Safety and Efficacy.

Authors:  Giovanni Corona; Alessandra Sforza; Mario Maggi
Journal:  World J Mens Health       Date:  2017-04-30       Impact factor: 5.400

5.  Assessment of Hypogonadism in Men With Type 2 Diabetes: A Cross-Sectional Study From Saudi Arabia.

Authors:  Ayman Abdullah Al Hayek; Asirvatham Alwin Robert; Ghazi Alshammari; Husain Hakami; Mohamed Abdulaziz Al Dawish
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2017-05-19

6.  The Association of Serum Testosterone Levels With Recurrence and Mortality After Acute Ischemic Stroke in Males.

Authors:  Chen-Hsun Ho; Chia-Chang Wu; Mei-Ching Lee; Pai-Hao Huang; Jen-Tse Chen; Shih-Ping Liu; Pin-Wen Liao
Journal:  Am J Mens Health       Date:  2019 May-Jun

Review 7.  Metabolic Disorders and Male Hypogonadotropic Hypogonadism.

Authors:  Rosario Pivonello; Davide Menafra; Enrico Riccio; Francesco Garifalos; Marco Mazzella; Cristina de Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-25       Impact factor: 5.555

Review 8.  Worse progression of COVID-19 in men: Is testosterone a key factor?

Authors:  Vito A Giagulli; Edoardo Guastamacchia; Thea Magrone; Emilio Jirillo; Giuseppe Lisco; Giovanni De Pergola; Vincenzo Triggiani
Journal:  Andrology       Date:  2020-06-28       Impact factor: 4.456

Review 9.  Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.

Authors:  Giuseppe Lisco; Anna De Tullio; Vito Angelo Giagulli; Edoardo Guastamacchia; Giovanni De Pergola; Vincenzo Triggiani
Journal:  Endocrine       Date:  2020-08-10       Impact factor: 3.633

Review 10.  Testosterone deficiency in non-cancer opioid-treated patients.

Authors:  F Coluzzi; D Billeci; M Maggi; G Corona
Journal:  J Endocrinol Invest       Date:  2018-10-20       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.